These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 17761994

  • 1. Reliable evidence of safety and efficacy of elderly patients in randomized clinical trials still needed.
    Crean SM, Reynolds MW, Dematto CA.
    J Clin Oncol; 2007 Sep 01; 25(25):4027-8; author reply 4028. PubMed ID: 17761994
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ, Panel of Experts in HCC-Design Clinical Trials.
    J Natl Cancer Inst; 2008 May 21; 100(10):698-711. PubMed ID: 18477802
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Multi-arm clinical trials of new agents: some design considerations.
    Freidlin B, Korn EL, Gray R, Martin A.
    Clin Cancer Res; 2008 Jul 15; 14(14):4368-71. PubMed ID: 18628449
    [Abstract] [Full Text] [Related]

  • 7. Designing phase III or IV trials for vaccines: choosing between individual or cluster randomised trial designs.
    Vaucher P.
    Vaccine; 2009 Mar 18; 27(13):1928-31. PubMed ID: 19368773
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. I don't like that, it's tricking people too much...: acute informed consent to participation in a trial of thrombolysis for stroke.
    Mangset M, Førde R, Nessa J, Berge E, Wyller TB.
    J Med Ethics; 2008 Oct 18; 34(10):751-6. PubMed ID: 18827109
    [Abstract] [Full Text] [Related]

  • 11. Incorporating predictions of individual patient risk in clinical trials.
    Kattan MW, Vickers AJ.
    Urol Oncol; 2004 Oct 18; 22(4):348-52. PubMed ID: 15283895
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Clinical trials and tribulations. Spiraling costs threaten gridlock.
    Malakoff D.
    Science; 2008 Oct 10; 322(5899):210-3. PubMed ID: 18845742
    [No Abstract] [Full Text] [Related]

  • 14. A personal view of some controversies in allocating treatment to patients in clinical trials.
    Cappelleri JC.
    Stat Med; 1996 Jan 15; 15(1):113-6. PubMed ID: 8614742
    [No Abstract] [Full Text] [Related]

  • 15. Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.
    Suman VJ, Dueck A, Sargent DJ.
    Cancer Invest; 2008 Jun 15; 26(5):439-44. PubMed ID: 18568764
    [No Abstract] [Full Text] [Related]

  • 16. Designing clinical trials for the treatment of delirium.
    Trzepacz PT, Bourne R, Zhang S.
    J Psychosom Res; 2008 Sep 15; 65(3):299-307. PubMed ID: 18707954
    [Abstract] [Full Text] [Related]

  • 17. Evaluating the risks and benefits of phase II and III cancer clinical trials: a look at Institutional Review Board members in the Netherlands.
    Van Luijn HE, Musschenga AW, Keus RB, Aaronson NK.
    IRB; 2007 Sep 15; 29(1):13-8. PubMed ID: 17855839
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.